Biovica FY26 operating loss narrows to 70.12 million; net sales rise 55% to 13.38 million

  • Biovica net sales more than doubled to SEK 4.82 million in fiscal Q4; operating loss narrowed to SEK 18.04 million.
  • Full-year net sales rose 55% to SEK 13.38 million; operating loss narrowed to SEK 70.12 million.
  • Cash and cash equivalents climbed to SEK 70.41 million; operating cash flow improved to SEK -62.81 million for the year.
  • Management cited growing US adoption of DiviTum TKa; the company is terminating an EU distribution contract to focus on the US and Pharma Services.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.